Idioma:

Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection

Clark, Natasha M ; Janaka, Sanath Kumar ; Hartman, William ; Stramer, Susan ; Goodhue, Erin ; Weiss, John ; Evans, David T ; Connor, Joseph P Jaworski, Juan Pablo

PloS one, 2022-03, Vol.17 (3), p.e0257930-e0257930 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por

Enviar para

Título:
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection
Autor: Clark, Natasha M ; Janaka, Sanath Kumar ; Hartman, William ; Stramer, Susan ; Goodhue, Erin ; Weiss, John ; Evans, David T ; Connor, Joseph P
Jaworski, Juan Pablo
Assuntos: ACE2 ; Adult ; Aged ; Aged, 80 and over ; Angiotensin-converting enzyme 2 ; Angiotensin-Converting Enzyme 2 - genetics ; Angiotensin-Converting Enzyme 2 - metabolism ; Antibodies ; Antibodies, Viral - blood ; Antibodies, Viral - immunology ; Antibodies, Viral - therapeutic use ; Biology and Life Sciences ; Coronaviruses ; COVID-19 ; COVID-19 - therapy ; COVID-19 - virology ; COVID-19 Serotherapy ; COVID-19 vaccines ; Ethylenediaminetetraacetic acid ; Fc receptors ; Female ; Health aspects ; HEK293 Cells ; Humans ; Immune response ; Immune system ; Immunization ; Immunization, Passive ; Immunoglobulin A ; Immunoglobulin A - blood ; Immunoglobulin A - immunology ; Immunoglobulin A - therapeutic use ; Immunoglobulin G ; Immunoglobulin G - blood ; Immunoglobulin G - immunology ; Immunoglobulin G - therapeutic use ; Immunoglobulin M ; Immunotherapy ; Infection ; Infections ; Isotypes ; Laboratories ; Male ; Medicine ; Medicine and Health Sciences ; Middle Aged ; Monoclonal antibodies ; Neutralization ; Neutralization Tests ; Neutralizing ; Pandemics ; Pathology ; Pharmaceutical industry ; Phosphoproteins ; Plasma ; Proteins ; Receptors ; Receptors, IgG - genetics ; Receptors, IgG - metabolism ; Research and Analysis Methods ; SARS-CoV-2 - isolation & purification ; SARS-CoV-2 - metabolism ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Spike Glycoprotein, Coronavirus - immunology ; Spike protein ; Transfusion ; Vaccination ; Vaccines ; Viral diseases ; Viral infections ; Viruses ; Young Adult
É parte de: PloS one, 2022-03, Vol.17 (3), p.e0257930-e0257930
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Competing Interests: The authors have declared that no competing interests exist.
Descrição: The novel coronavirus, SARS-CoV-2 that causes COVID-19 has resulted in the death of nearly 4 million people within the last 18 months. While preventive vaccination, and monoclonal antibody therapies have been rapidly developed and deployed, early in the pandemic the use of COVID-19 convalescent plasma (CCP) was a common means of passive immunization with a theoretical risk of antibody-dependent enhancement (ADE) of viral infection. Though vaccines elicit a strong and protective immune response and transfusion of CCP with high titers of neutralization activity are correlated with better clinical outcomes, the question of whether antibodies in CCP can enhance infection of SARS-CoV-2 has not been directly addressed. In this study, we analyzed for and observed passive transfer of neutralization activity with CCP transfusion. Furthermore, to specifically understand if antibodies against the spike protein (S) enhance infection, we measured the anti-S IgG, IgA, and IgM responses and adapted retroviral-pseudotypes to measure virus neutralization with target cells expressing the ACE2 virus receptor and the Fc alpha receptor (FcαR) or Fc gamma receptor IIA (FcγRIIA). Whereas neutralizing activity of CCP correlated best with higher titers of anti-S IgG antibodies, the neutralizing titer was not affected when Fc receptors were present on target cells. These observations support the absence of antibody-dependent enhancement of infection (ADE) by IgG and IgA isotypes found in CCP. The results presented, therefore, not only supports the therapeutic use of currently available antibody-based treatment, including the continuation of CCP transfusion strategies, but also the use of various vaccine platforms in a prophylactic approach.
Editor: United States: Public Library of Science
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection

Clark, Natasha M ; Janaka, Sanath Kumar ; Hartman, William ; Stramer, Susan ; Goodhue, Erin ; Weiss, John ; Evans, David T ; Connor, Joseph P Jaworski, Juan Pablo

United States: Public Library of Science

Buscando em bases de dados remotas. Favor aguardar.